Company news

Liquidia Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank

March 1, 2021

Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer

November 29, 2020

Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

November 24, 2020

Liquidia Closes Acquisition of RareGen

November 17, 2020

Liquidia Announces Results of Special Meeting of Stockholders

November 15, 2020

Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference

November 11, 2020

Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 8, 2020

Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC

November 1, 2020

Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020

October 29, 2020

Liquidia Announces Postponement of Special Meeting of Stockholders

October 18, 2020

Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents

October 13, 2020

Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development

October 4, 2020

Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC

September 16, 2020

Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil

August 27, 2020

Liquidia Announces Chief Financial Officer Transition

August 19, 2020

Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 9, 2020

Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

August 4, 2020

Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting

August 4, 2020

Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

August 2, 2020

Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent

July 23, 2020

Liquidia Announces Closing of Public Offering of Common Stock

July 1, 2020

Liquidia to Host Conference Call to Provide Update on Recent Announcements

June 28, 2020

Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH

June 28, 2020

Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents

June 4, 2020

Liquidia to Present at the Jefferies Virtual Healthcare Conference

May 26, 2020

Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer

May 17, 2020

Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 10, 2020

Liquidia to Report First Quarter 2020 Financial Results and Provide Corporate Update on May 11, 2020

May 5, 2020

Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

April 29, 2020

Liquidia to Present at the 19th Annual Needham Healthcare Conference

April 8, 2020

Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

April 7, 2020

Liquidia Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

March 10, 2020

Liquidia to Report 2019 Financial Results and Provide Corporate Update on March 11, 2020

February 25, 2020

Liquidia to Present at Cowen 40th Annual Health Care Conference

February 25, 2020

Liquidia Submits New Drug Application for LIQ861 (treprostinil) inhalation powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension (PAH)

January 26, 2020

Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)

January 23, 2020

Liquidia Technologies Announces $22.4 Million Private Placement

December 23, 2019

Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 12, 2019

Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019

November 5, 2019

Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors

October 31, 2019

Liquidia to Present at Cantor 2019 Global Healthcare Conference

September 24, 2019

Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors

September 11, 2019

Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions

April 2, 2019

Liquidia Technologies to Present at Needham Healthcare Conference

April 1, 2019

← Newer news releases

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.